The Oregon Department of Justice on Wednesday sued three of the nation’s largest insulin makers, accusing them of working with pharmacy benefit managers to drive up the price of a drug that diabetics ...

Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

Early prescription refills by U.S. pharmacies cost Medicare and patients $3B in 2021–2023, with mail-order pharmacies run by UnitedHealth (UNH) and Humana (HUM) leading the cost overruns, according to ...

(The Center Square) – Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report. Released by Hospital Spending Watch, the report examined how ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) About 1 in 5 U.S. adults skip filling a prescription due to its cost at least once a ...

Reining in 340B abuse is essential to protect employers and patients. The 340B Drug Discount Program was created to improve access to medications for low-income patients. But, like too many ...

Oregon Health & Science University leaders say a federal drug discount pilot set to begin next year could create a “significant cash-flow risk” for the institution and undermine its ability to serve ...

Share on Pinterest The TrumpRx prescription drug savings program is expected to be available by early 2026. Eli Lilly and Novo Nordisk have agreed to sell their weight-loss drugs, Wegovy and Zepbound, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Dr. Shereef Elnanal said he was ...

11/14/2025 Motion to extend the time to file a response from December 1, 2025 to January 15, 2026, submitted to The Clerk. 11/14/2025 Response of Express Scripts, Inc., et al. to motion submitted.